Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 601 to 650 of 1903 results for carers

  1. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.

    Highly specialised technologies guidance
    Published
    27 November 2019
    View recommendations

    Sections for HST12

  2. Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]

    Awaiting development [GID-TA11040] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822

    Awaiting development [GID-TA11229] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392

    Awaiting development [GID-TA11085] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769

    Awaiting development [GID-TA11088] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Sirolimus for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older [ID6440]

    In development [GID-TA11554] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Focal therapy using cryoablation for localised prostate cancer (IPG423)

    Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.

    Interventional procedures guidance
    Published
    26 April 2012
    View recommendations

    Sections for IPG423

  8. Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer (Review of TA662) [ID6404]

    Awaiting development [GID-TA11515] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development [GID-TA11404] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

    Awaiting development [GID-TA11367] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    Awaiting development [GID-TA11406] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    Awaiting development [GID-TA11166] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    Awaiting development [GID-TA11116] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    Awaiting development [GID-TA11344] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer TSID 10710

    Awaiting development [GID-TA11522] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  16. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    Awaiting development [GID-TA11336] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  17. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    Awaiting development [GID-TA11273] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  18. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    Awaiting development [GID-TA11342] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    Awaiting development [GID-TA11411] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  20. Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]

    Awaiting development [GID-TA11231] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  21. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    Awaiting development [GID-TA11021] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  22. Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

    Awaiting development [GID-TA11299] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  23. Depemokimab for treating chronic rhinosinusitis with nasal polyps TSID 12012

    Awaiting development [GID-TA11542] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  24. Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]

    Awaiting development [GID-TA11115] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  25. Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer [ID6346]

    Awaiting development [GID-TA11405] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  26. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  27. Advance care planning

    A quick guide for registered managers of care homes and home care services supporting advance care planning

    Social care quick guide
    Published
    21 April 2022

  28. Building independence through planning for transition

    NICE social care quick guide - building independence through planning for transition.

    Social care quick guide
    Published
    25 May 2022

  29. Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593

    Awaiting development [GID-TA10957] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  30. Dementia education and training programmes for family members and carers:- What is the effectiveness, cost effectiveness and acceptability of training programmes (forexample, in the use of life story work) for families of people growing older with learning disabilities who have dementia or are at risk of developing it?

    Question Dementia education and training programmes for family members and carers:- What is the effectiveness, cost effectiveness and...

    Research recommendation
    Published
    29 November 2018

  31. Ranibizumab port delivery system for treating diabetic macular oedema TS ID 10549

    Awaiting development [GID-TA11065] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  32. Gantenerumab for treating early Alzheimer's disease TS ID 10668

    Awaiting development [GID-TA11072] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  33. Insulin icodec for treating type 1 and type 2 diabetes TS ID 11770

    Awaiting development [GID-TA11104] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  34. Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237

    Awaiting development [GID-TA11328] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  35. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046

    Awaiting development [GID-TA11335] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  36. Bimekizumab for treating ankylosing spondylitis TS ID 10334

    Awaiting development [GID-TA11150] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  37. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer TS ID 10718

    Awaiting development [GID-TA11338] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  38. Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845

    Awaiting development [GID-TA11333] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over TS ID 11846

    Awaiting development [GID-TA11334] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  40. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer TS ID 11861

    Awaiting development [GID-TA11345] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  41. Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A TS ID 9772

    Awaiting development [GID-TA11329] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  42. Iptacopan for treating complement 3 glomerulopathy TS ID 10435

    Awaiting development [GID-TA11331] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  43. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592

    Awaiting development [GID-TA11332] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  44. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over TS ID 9130

    Awaiting development [GID-TA11325] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  45. Galcanezumab for migraine TS ID 10663

    Awaiting development [GID-TA11311] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  46. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777

    Awaiting development [GID-TA11292] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  47. Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over TS ID 10680

    Awaiting development [GID-TA11284] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  48. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer TS ID 11851

    Awaiting development [GID-TA11302] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  49. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer TS ID 11852

    Awaiting development [GID-TA11303] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  50. WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467

    Awaiting development [GID-TA11305] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development